Eurofins Softlines and Leather expands testing capabilities in China

(2 Apr 2020, Hong Kong) Eurofins Softlines and Leather is pleased to announce the expansion of its capabilities in China, demonstrating its confidence in and commitment to the market despite global uncertainty as a result of COVID-19.

Eurofins Softlines and Leather is proud to announce the consolidation of two laboratories in Hangzhou and Shenzhen as a Chinese testing hub for domestic and overseas customers specialising in the apparel and footwear industries. The Softlines and Leather laboratory in Shanghai has been smoothly and seamlessly relocated to the laboratory in Hangzhou. Such consolidation enables more comprehensive and effective service delivery facilitated by resource and workflow optimisation.

The Softlines and Leather laboratory in Shenzhen has received China Guobiao (GB) testing accreditation for textiles, footwear and leather products, demonstrating its robust technical expertise and capabilities in product quality and compliance. The newly approved testing scope strongly enhances the service portfolio of the Shenzhen laboratory as a testing hub in the region, and strengthens the positioning of Eurofins Softlines and Leather China in the global market.

ENDS

NOTES TO THE EDITOR:

About Eurofins SOFTLINES & LEATHER

As part of the Eurofins Consumer Product Testing (CPT) Division, Eurofins Softlines & Leather (S&L) delivers comprehensive quality, safety and sustainability solutions for textiles and footwear buyers and suppliers. Through its network of 10 laboratories in Asia, Europe and U.S., with two Technical Competence Centres in Spain and U.K., Eurofins S&L assists customers of all sizes in continuous product and supply chain improvement.    

About Eurofins – a global leader in bio-analysis

Eurofins Scientific, through its subsidiaries (hereinafter “Eurofins” or “the Group”), believes it is a global leader in food, environmental, pharmaceutical and cosmetics products testing and in agroscience CRO services. It is also one of the global independent market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, CDMO, advanced material sciences and in the support of clinical studies. In addition, Eurofins is one of the leading global emerging players in esoteric clinical diagnostic testing. With over 47,000 staff across a network of more than 900 independent companies in over 50 countries generally specialised by end client markets and operating more than 800 laboratories, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of biological substances and products, as well as providing innovative clinical diagnostic testing services. The Group’s objective is to provide customers with high-quality and innovative services, accurate results on time and, when requested, expert advice by its highly-qualified staff.

Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and a very large range of testing methods.

As one of the most innovative and quality-oriented international companies in its industry, Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the increasing demands of regulatory authorities and healthcare practitioners around the world.

Shares in Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).